Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-15 of 15
Keywords: Alzheimer’s disease
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Journal:
Pharmacology
Pharmacology (2021) 106 (7-8): 390–399.
Published Online: 12 May 2021
...Tugba Gulsun; Buket Ucar; Selma Sahin; Christian Humpel Introduction: Alzheimer’s disease (AD) is a severe neurodegenerative disorder of the brain characterized by degeneration of cholinergic neurons which is directly linked to cognitive decline. Nerve growth factor (NGF) is the most potent...
Journal Articles
Journal:
Pharmacology
Pharmacology (2020) 105 (5-6): 311–319.
Published Online: 20 March 2020
...Zhonglei Bao; Huixue Zhang; Hong Jiao; Xiaojie Chu; Jin Fu; Lihua Wang Introduction: The plaques formed by amyloid-β (Aβ) accumulation and neurofibrillary tangles formed by hyper-phosphorylated tau protein are the 2 major pathologies of Alzheimer’s disease (AD). Recently, autophagy is considered...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2018) 102 (1-2): 42–52.
Published Online: 29 May 2018
...Hande Karahan; Sevda Lüle; Pelin Kelicen-Uğur Background/Aims: Decreasing levels of aromatase and seladin-1 could be one of the molecular mechanisms of Alzheimer’s disease (AD). Aromatase is an enzyme that catalyzes estrogen biosynthesis from androgen precursors, and seladin-1 is an enzyme...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2016) 98 (5-6): 251–260.
Published Online: 28 July 2016
...Bianca Hutter-Schmid; Christian Humpel Alzheimer's disease (AD) is a severe neurodegenerative disorder of the brain, characterized by extracellular beta-amyloid (Aβ) plaques, intracellular tau pathology, neurodegeneration and inflammation. There is clear evidence that the blood-brain barrier...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2014) 94 (1-2): 1–12.
Published Online: 26 August 2014
...Yujie Cheng; Zhi Dong; Sha Liu Background/Aims: The activation of cannabinoid receptor 2 (CB2) has the beneficial effect of reducing neuroinflammatory response in the treatment of Alzheimer's disease (AD) and is suggested to trigger the peroxisome proliferator-activated receptor-γ (PPARγ) pathway...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2014) 93 (1-2): 57–64.
Published Online: 25 January 2014
.... Acetylcholine receptor Muscarinic receptor Memory Alzheimer’s disease Schizophrenia Muscarinic acetylcholine (ACh) receptors (mAChRs) have long been associated with memory processes [ 1 ]. Yet an unanswered question is how each of the 5 mAChR subtypes influences memory, a question that has important...
Journal Articles
Subject Area:
Pharmacology
Kimiko Konishi, Koji Hori, Hiroi Tomioka, Genshin Minegishi, Masayuki Tani, Hiroaki Tanaka, Ryo Akita, Sachiko Yokoyama, Tomonori Oshio, Mitsugu Hachisu
Journal:
Pharmacology
Pharmacology (2013) 91 (1-2): 86–91.
Published Online: 14 December 2012
... treatment with the cholinesterase inhibitor donepezil for 1 year. Her only other regular medications were topical glaucoma preparations. We suggest that mental stress, mild cognitive impairment and Alzheimer’s disease pathology combined to generate SAA in this patient. We also consider that SAA may have...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2010) 85 (1): 1–17.
Published Online: 18 November 2009
.... Alzheimer’s disease Parkinson’s disease Huntington’s disease Spinocerebellar ataxia Multiple systemic atrophy Niemann-Pick disease Progressive supranuclear palsy Amyotrophic lateral sclerosis Prions Amyloid proteins Cholesterol Mitochondria Review Pharmacology 2010;85:1 17 DOI: 10.1159/000259044...
Journal Articles
Subject Area:
Pharmacology
Jennifer S. Kiefer-Day, El-Sayed A.M. Abdallah, Carlos Forray, Norman H. Lee, Ok Nyu Kim, Esam E. El-Fakahany
Journal:
Pharmacology
Pharmacology (1993) 47 (2): 98–110.
Published Online: 10 June 2008
...-Amino-1,2,3,4- tetrahydroacridine Tacrine® Muscarinic receptor Cholinesterase inhibitor Alzheimer’s disease Memory enhancer Second messengers Signal transduction Original Paper Pharmacology 1993;47:98-110 Jennifers. Kiefer-Day El-Sayed A.M. Abdallah Carlos Forray Norman H. Lee Ok Nyu Kim Esam...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (1992) 44 (2): 71–80.
Published Online: 06 June 2008
...: Tacrine, a drug with therapeutic potential for dementia: Post-mortem biochemi cal evidence. Can J Neurol Sci 1989: 16:504-510. 11 Kumar V. Becker RE: Clinical phar macology of letrahydroaminoacridine: A possible therapeutic agent for Alzheimer's disease. Int J Clin Pharmacol Ther Toxicol 1989:27: 478...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2007) 80 (4): 286–292.
Published Online: 02 August 2007
... in an intact astroglial network, which might be of importance in neurodegenerative diseases, such as Alzheimer’s disease. 10 04 2007 17 04 2007 2 8 2007 © 2007 S. Karger AG, Basel 2007 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2007) 79 (1): 17–26.
Published Online: 28 November 2006
...A. Kumar; P.S. Naidu; N. Seghal; S.S.V. Padi Alzheimer’s disease is a complex and multifactorial neurodegenerative disease. Central administration of colchicine, a microtubule-disrupting agent, causes loss of cholinergic neurons and cognitive dysfunction that is associated with excessive free...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2005) 74 (2): 65–78.
Published Online: 26 May 2005
...Laurent Lecanu; Yao Wenguo; Jing Xu; Janet Greeson; Vassilios Papadopoulos Alzheimer’s disease (AD) is the most common dementia occurring in elderly. We report herein the neuroprotective properties of procaine and other anesthetic agents against β-amyloid-induced neurotoxicity. Procaine displayed...
Journal Articles
Subject Area:
Pharmacology
Imrich Blasko, Thomas Bodner, Gabriele Knaus, Thomas Walch, Andreas Monsch, Hartmann Hinterhuber, Josef Marksteiner
Journal:
Pharmacology
Pharmacology (2004) 72 (1): 1–5.
Published Online: 06 August 2004
...Imrich Blasko; Thomas Bodner; Gabriele Knaus; Thomas Walch; Andreas Monsch; Hartmann Hinterhuber; Josef Marksteiner In a pilot study designed as a case control study the efficacy of donepezil treatment was investigated in patients with Alzheimer’s disease (AD). Patients were stratified according...
Journal Articles
Subject Area:
Pharmacology
Journal:
Pharmacology
Pharmacology (2000) 60 (2): 82–89.
Published Online: 16 February 2000
.... Choline Muscarinic acetylcholine receptors M 1 subtype Neuronal nitric oxide synthase Calcium signaling Alzheimer’s disease Original Paper Pharmacology 2000;60:82 89 Received: March 1, 1999 Accepted: June 15, 1999 Choline Is a Full Agonist in Inducing Activation of Neuronal Nitric Oxide Synthase...